Centene Corporation (CNC) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2025. Centene Corporation is the nation's largest managed care company focused on underserved populations, operating in four segments: Medicaid, Medicare, Commercial, and Other. As of year-end 2025, the company served 27.6 million members, a 3% decrease from 2024, driven primarily by Medicaid redeterminations and strategic Medicare Advantage exits, partially offset by growth in the Marketplace and Medicare Part D (PDP) segments.
Key Financial Metrics
| Metric ($ in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $194,777 | $163,071 | +19% |
| Premium & Service Revenues | $174,581 | $145,505 | +20% |
| Medical Costs | $157,702 | $125,707 | +25% |
| Health Benefits Ratio (HBR) | 91.9% | 88.3% | +360 bps |
| SG&A Expense Ratio | 7.4% | 8.5% | -110 bps |
| GAAP Net Earnings (Loss) | $(6,674) | $3,305 | Turn to Loss |
| GAAP Diluted EPS | $(13.53) | $6.31 | N/A |
| Adjusted Net Earnings | $1,028 | $3,753 | -73% |
| Adjusted Diluted EPS | $2.08 | $7.17 | -71% |
| Operating Cash Flow | $5,088 | $154 | Significant Increase |
| Total Debt | $17,401 | $18,533 | -6% |
Material Changes vs. Prior Period
- Significant Impairment Charges: The company recorded a non-cash goodwill impairment of $6.7 billion in Q3 2025, primarily affecting the Medicaid and Commercial reporting units. This was driven by the passage of the "One Big Beautiful Bill Act" (OBBBA), potential membership impacts, and a decline in stock price. Additional impairments included $513 million for Magellan Health (held for sale) and $55 million for intangible assets.
- Medical Cost Trends: The HBR increased to 91.9% due to higher medical costs in Medicaid (behavioral health, home health, high-cost drugs) and the Commercial segment (lower risk adjustment revenue, higher morbidity). The Medicare segment saw increased costs due to Inflation Reduction Act (IRA) changes shifting cost-sharing responsibilities to plans.
- Membership Shifts: Medicaid membership declined due to redeterminations following the end of the public health emergency. Conversely, PDP membership grew 17% due to strong bid positioning, and Marketplace membership grew 26% due to footprint expansion.
- Divestitures: In December 2025, Centene signed a definitive agreement to divest the remaining Magellan Health businesses. The assets are classified as held for sale.
Guidance, Outlook, and Risks
- Regulatory Impact (OBBBA): The OBBBA, passed in July 2025, introduces work requirements for Medicaid Expansion, more frequent eligibility redeterminations, and cost-sharing measures. These changes are expected to increase the morbidity of the Medicaid population starting in 2027 and may reduce federal funding via provider tax adjustments starting in 2028.
- Marketplace Outlook: The expiration of Enhanced Advance Premium Tax Credits (APTCs) at the end of 2025, combined with the OBBBA and new program integrity rules, is expected to reduce 2026 Marketplace membership and increase population morbidity. Centene has taken corrective pricing actions for 2026 covering 95% of its Marketplace membership.
- Medicare Part D: IRA changes effective in 2025 eliminated the coverage gap and capped out-of-pocket costs, significantly increasing plan liability. For 2026, CMS eliminated narrowed risk corridors, shifting PDPs back to standard financial risk-sharing.
- Liquidity: The company maintains a strong liquidity position with $5.1 billion in operating cash flow for 2025. It has a $4.0 billion Revolving Credit Facility (unutilized) and $1.8 billion remaining under its stock repurchase program.
- Legal Proceedings: A putative federal securities class action was filed in July 2025 alleging false statements regarding 2025 earnings guidance. The company denies wrongdoing and is vigorously defending the claims.
Investor Verification Checklist
- Goodwill Impairment Assumptions: Verify the discounted cash flow models and market multiples used to justify the $6.7 billion impairment, specifically regarding the impact of the OBBBA on future Medicaid and Commercial cash flows.
- Medical Claims Liability Reserves: Review the actuarial assumptions for Incurred But Not Reported (IBNR) claims, particularly given the noted acceleration in medical cost trends and the sensitivity of the HBR to these estimates.
- 2026 Pricing Adequacy: Assess whether the corrective pricing actions taken for 2026 Marketplace plans are sufficient to offset the anticipated increase in morbidity following the expiration of Enhanced APTCs.
- Magellan Health Divestiture: Monitor the timeline and terms of the Magellan Health divestiture to ensure the $513 million impairment charge is not a precursor to further write-downs or integration costs.
- Part D Receivables: Confirm the collectability and timing of the $4.0 billion receivable from CMS for 2025 Part D risk-sharing programs, especially given the new receivable purchase agreement entered into in February 2026.